An acridine derivative including a structure of formula (I) is provided. The acridine derivative can be used as a fluorescent material, in particular, it is included in an organic light-emitting layer as a dark blue thermally-activated delayed fluorescent material, thereby a series of high-performance electrothermally activated delayed fluorescent devices are produced.

Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

The invention discloses an ifosfamide intermediate, a preparation method and application thereof. The ifosfamide intermediate has formula I. The ifosfamide intermediate reacts with a chlorinating agent, and then cyclization is performed under the action of an organic base to obtain ifosfamide. Compared with the existing synthetic routes, the method of the invention has the advantages that the use of highly toxic and explosive ethyleneimine can be avoided, and the use of explosive chemicals can be avoided.

##STR00001##

The present invention relates to heterocyclic compounds, especially for use in electronic devices. The invention further relates to a process for preparing the compounds of the invention and to electronic devices comprising these.

The present invention relates to 5,6-diphenyl-5,6-dihydrodibenz[c,e][1,2]azaphosphorin and 6-phenyl-6H-dibenzo[c,e][1,2]thiazine 5,5-dioxide derivatives and similar compounds of the formula (1) as organic electroluminescent materials for use in organic electroluminescent devices, for example in organic light-emitting diodes (OLEDs), where the symbols used are as follows: Z is the same or different at each instance and is PAr.sup.2 or S(═O); E is the same or different at each instance and is O or S when the symbol Z to which this E binds is PAr.sup.2, and O when the symbol Z to which this E binds is S(═O); L is selected from the group consisting of a single bond, NAr.sup.2, O, S, S(═O).sub.2, P(═O)Ar.sup.2, —X═X— and —C(═O)—NAr.sup.2; the rest of the symbols are defined in the claims. The present invention discloses synthesis examples of inventive compounds, productions of OLEDs containing these example compounds, and results for these electroluminescent devices.

The invention relates to oligomerization of olefins, such as ethylene, to higher olefins, such as a mixture of 1-hexene and 1-octene, using a catalyst system that comprises a) a source of chromium b) one or more activators and c) a phosphacycle-containing ligating compound. Additionally, the invention relates to a phosphacycle-containing ligating compound and a process for making said compound.

The invention discloses an ifosfamide intermediate, a preparation method and application thereof. The ifosfamide intermediate has formula I. The ifosfamide intermediate reacts with a chlorinating agent, and then cyclization is performed under the action of an organic base to obtain ifosfamide. Compared with the existing synthetic routes, the method of the invention has the advantages that the use of highly toxic and explosive ethyleneimine can be avoided, and the use of explosive chemicals can be avoided. ##STR00001##

The present application relates to antibodies that bind to small molecules such as cyclophosphamide, ifosfamide, and analogs thereof, and immunological assays for determining the presence and/or quantifying the amount of cyclophosphamide and/or ifosfamide in a sample. By way of example, such immunological assays can be used for environmental testing.

Described are compounds that act as AKR1C3 inhibitors or pharmaceutically acceptable salts or solvates or isotopically substituted compounds thereof and methods thereof.

Provided herein are prodrug compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in molecular pathways in the liver.